Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

Molecular target inhibitors have been regularly approved by Food and Drug Administration (FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and metabolism. The RAS–RAF–MEK–ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation, surviv...

Full description

Bibliographic Details

Published in:	Genes and Diseases
Main Authors:	Yanlin Song, Zhenfei Bi, Yu Liu, Furong Qin, Yuquan Wei, Xiawei Wei
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2023-01-01
Subjects:	Clinical trials Molecular target therapy RAS–RAF–MEK–ERK signaling pathway
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304222001404